drugset
drugset / Trial / NCT04607655

A Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Orally Administered GB1211 in Participants With Suspected or Confirmed Non-alcoholic Steatohepatitis (NASH) and Liver Fibrosis

NCT04607655 ↗

Phase 1/2 Withdrawn Galecto Biotech AB Covance · collab
RandomizedParallel-groupQuadruple-blindTreatment

Summary

This study is a randomised, double-blind, placebo controlled, phase Ib trial in subjects with suspected or confirmed non-alcoholic steatohepatitis (NASH) and liver fibrosis

Timeline

Start
2021-03
Primary completion
2022-07
Completion
2022-07

Outcome

Outcome not reported

Stopped (Business): “Due to COVID-19 pandemic and change in the clinical development strategy for the GB1211 compound”

Drugs

EvaluationDrugModalityDoseRoute
Subject Selvigaltin Small molecule 10 mg Oral
Subject Selvigaltin Small molecule 100 mg Oral

Indications

metabolic dysfunction-associated steatohepatitis